Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apraglutide for treating short bowel syndrome [ID6533]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC